Patents by Inventor Richard Ulevitch

Richard Ulevitch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOD1 as an anti-tumor agent
    Publication number: 20060194740
    Abstract: The invention provides compositions and methods for treating tumors that involve increasing the expression of Nod1 and/or the activity of NOD1.
    Type: Application
    Filed: February 23, 2006
    Publication date: August 31, 2006
    Inventors: Richard Ulevitch, Jean Silva, Jiahuai Han
  • Methods and compositions for inhibiting CD14 mediated cell activation
    Publication number: 20060073145
    Abstract: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.
    Type: Application
    Filed: September 3, 2002
    Publication date: April 6, 2006
    Inventors: Didier Leturcq, Ann Moriarty, Richard Ulevitch, Peter Tobias, John Mathison
  • Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use
    Patent number: 6884417
    Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: April 26, 2005
    Assignee: The Scripps Research Institute
    Inventors: Theo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
  • Methods and compositions for ameliorating the symptoms of sepsis
    Patent number: 6495332
    Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: December 17, 2002
    Assignees: The Sripps Research Institute, The Rockefeller University
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Methods and compositions for ameliorating the symptoms of sepsis
    Publication number: 20020034509
    Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Application
    Filed: October 2, 2001
    Publication date: March 21, 2002
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use
    Publication number: 20010029292
    Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Application
    Filed: May 15, 2001
    Publication date: October 11, 2001
    Applicant: The Scripps Research Institute
    Inventors: Theo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
  • Methods and compositions for ameliorating the symptoms of sepsis
    Patent number: 6297049
    Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: October 2, 2001
    Assignee: The Scripps Research Institute
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use
    Patent number: 6232080
    Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: May 19, 1998
    Date of Patent: May 15, 2001
    Assignee: The Scripps Research Institute
    Inventors: Theo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
  • Methods and compositions for ameliorating the symptoms of sepsis
    Patent number: 6045795
    Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CDl4 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: April 4, 2000
    Assignee: The Scripps Research Institute
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use
    Patent number: 5753504
    Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: May 19, 1998
    Assignee: The Scripps Research Institute
    Inventors: Theo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
  • Methods and compositions for ameliorating the symptoms of sepsis
    Patent number: 5730980
    Abstract: The present invention concerns a method of treating CD14-mediated host inflammatory response to LPS often associated with sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: March 24, 1998
    Assignee: The Scripps Research Institute
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Methods for identifying inhibitors of LPS-mediated LBP binding
    Patent number: 5705398
    Abstract: The present invention describes a rapid method for the identification of compounds/reagents which inhibit lipopolysaccharide (LPS) binding to LPS binding protein (LBP), and kits for practicing the method.
    Type: Grant
    Filed: March 2, 1994
    Date of Patent: January 6, 1998
    Assignee: The Scripps Research Institute
    Inventors: Douglas N. Mintz, Peter Tobias, Richard Ulevitch
  • Acute phase protein modulating endotoxic activity of lipopolysaccharides, assay methods and polypeptides
    Patent number: 5245013
    Abstract: A lipopolysaccharide binding protein is disclosed as are an assay method, polypeptides and antibodies related to that binding protein. The binding protein: (a) is present in impure form in acute phase serum, but is substantially absent from normal serum; (b) binds to Gram-negative bacterially secreted lipopolysaccharide in vitro in the serum of the animal treated; (c) retards in vitro binding of the lipopolysaccharide to high density lipoprotein present in the normal serum of the animal host; and (d) immunoreacts with antibodies raised to a polypeptide having the amino acid residue sequence, from left to right and in the direction from amino-terminus to carboxy-terminus, or ##STR1## wherein each of said parenthesized amino acid residues in an alternative to the immediately preceding residue in said sequence.
    Type: Grant
    Filed: June 16, 1989
    Date of Patent: September 14, 1993
    Inventors: Richard Ulevitch, Peter Tobias